Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Reynolds

Showing results (171-180 of 212) with videos related to

Pageof 22
Sort By:
Pediatric Blood & Cancer|September 30, 2014
Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673Malcolm A Smith, Oliver A Hampton, C Patrick Reynolds, et al.
Pediatric Blood & Cancer|July 2, 2013
Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortiumBarry J Maurer, Min H Kang, Judith G Villablanca, et al.
Pediatric Blood & Cancer|September 17, 2011
Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing programMalcolm A Smith, Richard Gorlick, E Anders Kolb, et al.
The New England Journal of Medicine|October 1, 2010
Outcome after reduced chemotherapy for intermediate-risk neuroblastomaDavid L Baker, Mary L Schmidt, Susan L Cohn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2006
A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology GroupKaci L Osenga, Jacquelyn A Hank, Mark R Albertini, et al.
Molecular Cancer Therapeutics|January 8, 2010
Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing ProgramPeter J Houghton, Christopher L Morton, Richard Gorlick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2015
Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing's family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expressionMin H Kang, Jing Wang, Monish R Makena, et al.
Pediatric Blood & Cancer|September 24, 2015
Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing programEdward F Attiyeh, John M Maris, Richard Lock, et al.
Pediatric Blood & Cancer|July 12, 2011
Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing programPeter J Houghton, Richard Lock, Hernan Carol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2025
Frequency and Clinical Significance of Clonal and Subclonal Driver Mutations in High-Risk Neuroblastoma at Diagnosis: A Children's Oncology Group StudyEsther R Berko, Arlene Naranjo, Alexander A Daniels, et al.
Pageof 22

Showing results (171-180 of 212) with videos related to

Sort By:
Pageof 22
Pediatric Blood & Cancer|September 30, 2014
Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673Malcolm A Smith, Oliver A Hampton, C Patrick Reynolds, et al.
Pediatric Blood & Cancer|July 2, 2013
Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortiumBarry J Maurer, Min H Kang, Judith G Villablanca, et al.
Pediatric Blood & Cancer|September 17, 2011
Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing programMalcolm A Smith, Richard Gorlick, E Anders Kolb, et al.
The New England Journal of Medicine|October 1, 2010
Outcome after reduced chemotherapy for intermediate-risk neuroblastomaDavid L Baker, Mary L Schmidt, Susan L Cohn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2006
A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology GroupKaci L Osenga, Jacquelyn A Hank, Mark R Albertini, et al.
Molecular Cancer Therapeutics|January 8, 2010
Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing ProgramPeter J Houghton, Christopher L Morton, Richard Gorlick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2015
Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing's family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expressionMin H Kang, Jing Wang, Monish R Makena, et al.
Pediatric Blood & Cancer|September 24, 2015
Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing programEdward F Attiyeh, John M Maris, Richard Lock, et al.
Pediatric Blood & Cancer|July 12, 2011
Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing programPeter J Houghton, Richard Lock, Hernan Carol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2025
Frequency and Clinical Significance of Clonal and Subclonal Driver Mutations in High-Risk Neuroblastoma at Diagnosis: A Children's Oncology Group StudyEsther R Berko, Arlene Naranjo, Alexander A Daniels, et al.
Pageof 22